Caristo Diagnostics' CaRi-Heart® Coronary Inflammation Technology Authorized by U.S. FDA

RegulatoryapprovedCaRi-Heart®Positive

AI Analysis

Summary

Caristo Diagnostics announced FDA authorization of CaRi-Heart, the first biomarker technology to measure coronary inflammation and assess cardiovascular mortality risk. The CaRi-Heart Risk score can identify cardiovascular risk up to 10 years in advance, enabling personalized disease management.

Outcome Details

FDA authorization for CaRi-Heart coronary inflammation biomarker; first and only biomarker to measure coronary inflammation and assess cardiovascular mortality risk

Importance:8/10

Sentiment:

0.85

FDA approvalcardiovascularbiomarkerdiagnosticscoronary inflammationrisk stratification

Related Companies

$ONT.L $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 29, 2026 2:00 PM

Read Original